Bicycle Therapeutics PLC expected to post a loss of $1.17 a share - Earnings Preview

Bicycle Therapeutics

30/10/2023 15:35

* Bicycle Therapeutics PLC  BCYC.OQ   BCYC.O  is expected
to show
a rise in quarterly revenue when it reports  results 
    * The Cambridge Cambridgeshire-based  company is expected to
report  a 330.5% increase in revenue to $13.088 million from
$3.04 million a year ago, according to the mean estimate from 13
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Bicycle
Therapeutics PLC
is for a loss of $1.17 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bicycle
Therapeutics PLC is $47​, above​ its last closing price
of $14.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.31       -1.29      -1.41     Missed  -9
 Mar. 31 2023  -1.08       -1.07      -1.30     Missed  -21.1
 Dec. 31 2022  -1.05       -1.06      -1.01     Beat    4.6​
 Sep. 30 2022  -0.86       -0.89      -0.96     Missed  -8
 ​​Jun.        -0.89       -0.85      -0.90     Missed  -6.1
 30 2022                                                
 Mar. 31 2022  -0.70       -0.68      -0.93     Missed  -36.4​
 Dec. 31 2021  -0.67       -0.61      -0.63     Missed  -3.1
 Sep. 30 2021  -0.63       -0.61      -0.59     Beat    3.5
 This summary was machine generated October 30 at 15:35 GMT.  All
figures in US dollars  unless otherwise stated